According to a study published in the journal The Lancet last Friday, long term use and daily doses of aspirin have led to a decrease of about 60% in cases of colorectal cancer among people with an inherited risk of the disease.
The trial of the study which was considered as broad in sample and long in duration have confirmed evidence elsewhere that aspirin has a defensive effect against colon and rectal cancer. The study made use of patients with Lynch Syndrome, a condition wherein genes have been faulted to have cellular repair leading to colorectal cancer and other forms of cancer. This certain syndrome occurs in about one out of every 1,000 people and accounted for about one out of thirty cases of bowel cancer, according to The Lancet journal.
About 861 individuals were randomly picked to take either two aspirin doses of 600 mg each, or a harmless placebo pill, both options to be taken for at least two years. These people were asked to undergo colon cancer screening tests.
In the initial examination of their data last 2007, no difference in terms of colorectal incidence was noticed between both groups. However, a few years later, the researchers found some significant changes.
During the follow up check conducted, there had been 34 cases of colorectal cancer in people taking placebo. In terms of those taking aspirin, there were 19 patients who developed colon cancer. This points out to a 44% difference in the incidence of colorectal cancer.
The physicians further investigated the patients who took aspirin or the placebo beyond the two-year period. The figures were more impressive in this certain sub group.
23 cancers were recorded in the group taking placebo drug but only 10 in the aspirin group developed the said cancer. This pertains to a decline of 63% and the difference started to become evident after five years.
In relation to this discovery, more research has been set out in order to determine the best dosage and duration of aspirin treatment. “In the meantime, clinicians should consider aspirin prescription for all individuals judged to be at high risk of colorectal cancer, but taking appropriate measures to minimise adverse effects,” according to the paper, headed by John Burn, who is a professor of clinical genetics at Newcastle University, northeastern England.
Last 2010, The Lancet also published a study which found out that the rate for colon cancer, prostate, lung and brain cancer were all cut down with daily aspirin use. For colon cancer, the risk over 20 years was cut down by forty percent.
Doctors claim that regular use of aspirin also lowers the risk of heart attack, clot related strokes and other problems with regard to blood flow. Extended daily use of aspirin, however, has been linked to a number of stomach problems.